Navigation Links
Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an
Date:5/23/2013

TOKIO, 22. Mai 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (im Weiteren Ranbaxy), eine Tochtergesellschaft von Daiichi Sankyo Co., Ltd. (im Weiteren Daiichi Sankyo), gab am 22. Mai die Maßnahmen bekannt, die Ranbaxy in den letzten Jahren ergriffen hat, um sich der Angelegenheiten der vorhergehenden Unternehmensführung anzunehmen.

(http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html).

Daiichi Sankyo unterstützt Ranbaxy weiterhin dabei, die Fehler der vorhergehenden Geschäftsführung zu korrigieren, welche zu Untersuchungen durch das Justizministerium der Vereinigten Staaten und die US-Arzneimittelzulassungsbehörde („USFDA") geführt hatten. Die Änderungen, die bei Ranbaxy vorgenommen werden sollen, umfassen die Geschäftsführung, die Unternehmenskultur, den Betrieb und die Compliance.

Daiichi Sankyo geht davon aus, dass bestimmte ehemalige Aktionäre von Ranbaxy wichtige Informationen hinsichtlich der Untersuchungen durch das US-Justizministerium und die FDA verschwiegen und falsch dargestellt haben. Daiichi Sankyo prüft derzeit die verfügbaren Rechtsmittel und kann das Thema nicht weiter kommentieren.

Informationen zu Daiichi Sankyo Co., Ltd. 
Börsennotierung: Börsenkürzel: 4568, Erster Index der Börsen in Tokio, Osaka und Nagoya
Präsident und CEO: Joji Nakayama

Kontakt: 
Noriaki Ishida 
Corporate Officer & Vice President 
Abteilung für Unternehmenskommunikation
Daiichi Sankyo Co., Ltd. 
Tel.: +81-3-6225-1126 
E-Mail: kondo.toshiya.cj@daiichisankyo.co.jp

http://www.daiichisankyo.com/


'/>"/>
SOURCE Daiichi Sankyo Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
2. Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years
3. Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
4. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
5. Ranbaxy to Market Desvenlafaxine Base Extended Release Tablets in the U.S.
6. Indias Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud
7. Statement By Dinesh Thakur Regarding US Governments Case Against Ranbaxy
8. Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives
9. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
10. Simbionix kündigt Lizenzvertrag für chirurgische Videos an
11. Blue Belt Technologies kündigt Gründung eines wissenschaftlichen Beirats für Hüfteingriffe zur Bestimmung neuer Anwendungsgebiete von NavioPFS bei femoro-acetabulärem Impingement an
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the ... President of R&D and Head of Virology Kristin Bedard has ... the Northwest and Beyond meeting sponsored by Life Science ... from 8:30-10:30 AM PDT at the Agora Conference Center in ... Bedard will be joined by other leaders in infectious disease ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader in ... position of Executive Vice President, Sales and Marketing. Finnegan is a widely known ... device sales leadership. He has received industry recognition for innovations and new approaches ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands ... whether they can trust the sponsor to pay them correctly and on time. As ... CROs establish payment strategies that encourage sites to work on their studies. , At ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the ... the health care industry’s hospitals and provider groups, has announced that it will ... customers. Parasail Health is a San Francisco health-finance startup that has launched a ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
(Date:6/27/2017)... Beverly Hills, California (PRWEB) , ... June 27, 2017 , ... ... implants market has been projected to reach a staggering $6.81 billion by the year ... implants are rising at a faster rate than those made from titanium. Los Angeles ...
Breaking Medicine News(10 mins):